Skip to main content

Table 1 Demographic and clinical features of study population

From: The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis

  Total Osteoporosis Osteopenia Normal p
(N = 1322) (N = 619) (N = 582) (N = 121)
Age 61.2 ± 8.2 63.7 ± 8.2 59.8 ± 7.3 55.1 ± 6.6 <0.001
BMI (kg/m2) 22.9 ± 3.1 22.0 ± 3.2 23.4 ± 2.9 24.7 ± 3.3 <0.001
Disease duration (yrs) 12.1 ± 9.9 13.9 ± 10.6 10.9 ± −9.3 9.1 ± −8.7 <0.001
Previous fracture (N, %)
 Vertebrae 40 (3.0) 23 (1.7) 17 (1.3) 0 (0.0) 0.090
 Femur 24 (1.8) 19 (1.4) 5 (0.4) 0 (0.0) 0.004
 Wrist 66 (5.0) 38 (2.9) 27 (2.0) 1 (0.1) 0.042
 Upper arm 16 (1.2) 11 (0.8) 5 (0.4) 0 (0.0) 0.154
 Othersa 171 (12.9) 95 (7.2) 65 (74.9) 11 (0.8) 0.041
Use of GC (N, %) 1027 (77.7) 498 (80.5) 439 (75.4) 90 (74.4) 0.074
Current dose of GC (mg/day) 4.3 ± 2.5 4.4 ± 2.7 4.2 ± 2.4 4.4 ± 2.1 0.581
Cumulative dose of GC (g*mo)b 5.4 ± 7.0 6.7 ± 7.7 4.4 ± 6.4 3.6 ± 6.1 <0.001
HAQ (0–3) 0.9 (1.0) 1.0 (1.1) 0.8 (0.9) 0.6 (0.9) <0.001
DAS28-ESR 4.0 (1.8) 3.9 (1.9) 4.0 (1.8) 3.8 (1.5) 0.120
ESR (mm/h) 26.0 (32.0) 25.0 (32.0) 28.0 (33.0) 24.0 (27.0) 0.240
CRP (mg/dL) 0.3 (0.8) 0.3 (0.8) 0.3 (0.9) 0.2 (0.5) 0.058
RF, positivity (N, %) 1158 (87.7) 545 (88.2) 510 (87.6) 103 (85.1) 0.644
ACPA, positivity (N, %) 899 (84.3) 395 (83.5) 418 (85.5) 86 (81.9) 0.551
  1. Values shown are median (interquartile range), mean ± standard deviation and frequency (percentage)
  2. BMI bone mass index, BMD bone mineral density, GC glucocorticoid, HAQ health assessment questionnaire, DAS 28-ESR Disease Activity Score 28 using ESR, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic-citrullinated protein antibody
  3. aNasal bone, clavicle, shoulder, scapula, rib, hand, pelvic bone, ankle, feet, coccyx
  4. bDose of glucocorticoids according prednisolone × 30 × months/1000